CClinicalTrials.gg
RecruitingNCT06884046Et APRéS CaUpdated Mar 19, 2025

Support for the Management of Parental Stress in Surgical Resuscitation of Congenital Heart Diseases

An interventional study of Personalized support project in Complex Congenital Heart Disease, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
0 Days to 28 Days
Sex
All
01

Study summary

Half of children with congenital heart disease develop specific neurodevelopmental disorders. Neurodevelopmental disorders are the leading cause of morbidity in these children. They can be increased by perioperative complications, the family and economic socio-economic environment and the level of parental stress. The stress perceived by parents of children with congenital heart disease varies depending on the time of diagnosis, the organization of care inherent in neonatal management and the type of pathology diagnosed.

The main objective is to evaluate the feasibility of a multidisciplinary and personalised model of support for parental stress, from the ante-natal period, in the context of their child's neonatal cardiac surgery.

Read the detailed description

Congenital heart disease (CC) is the most common congenital malformation. Every year, 8 newborns out of 1000 are affected by these pathologies worldwide and about 20% of them will require intervention in the first days of life. The complexity of heart disease, factors intrinsic to the patient as well as surgical techniques can be the cause of neurological abnormalities. Indeed, 43% of these CC newborns are already carriers of a cerebral anomaly in the perinatal period.

Neurodevelopmental disorders (NDD) are the leading cause of morbidity in these children. They can be increased by perioperative complications, the family and economic socio-economic environment and the level of parental stress. The stress perceived by parents of children with CC varies depending on the time of diagnosis, the type of pathology and the organization of neonatal care.

It is essential to accompany these parents with personalized care. It must be comprehensive, multidisciplinary and empathetic, with the aim of improving the neurodevelopmental prognosis of these children, and family well-being.

Through this project of accompaniment proposed from the antenatal, we innovate by integrating consultations by the paramedical team of the resuscitation, the implementation of a personalized support project that meets the expectations and needs of families for better care of their child. A parental stress assessment will be carried out at 4 times of the family care journey.

02

Conditions studied

  • Complex Congenital Heart Disease

Keywords

  • Neurodevelopment
  • Stress parental
  • Parental guidance
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's planned enrollment of 40 is below the median of 100 across 1,778 interventional studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 783 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Parents whose fetus has congenital heart disease diagnosed in antenatal, which will be operated in the neonatal period (between 0 and 28 days of life) within our sector.
  • Parents followed in the congenital heart disease sector of the University Hospital of Bordeaux as soon as the diagnosis is announced in antenatal.
  • Free, informed and signed written consent of the couple or single mother in a single parent setting or by a third person (in case of physical disability of the participant) and the investigator (no later than the day of inclusion and before any examination required by the research).
  • Person affiliated or beneficiary of a social security scheme (excluding AME).
  • Parents with parental authority.

Exclusion criteria

Exclusion Criteria:

  • Parents who do not understand or read French and cannot be accompanied by a third party for translation.
  • Parents with major psychiatric disorders.
  • Parents deprived of liberty due to ongoing legal proceedings.
  • Parents under guardianship or curatorship or unable to personally express consent.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Accompaniment project

    The experimental intervention envisaged combines specific monitoring and the implementation of a personalised support programme.

    Other: Personalized support project

Interventions

  • OtherPersonalized support project

    1. Presence of a child nurse at the consultation of the anesthesiologist-resuscitator. 2. Antenatal paramedical consultation conducted by a child nurse composed of a semi-structured interview and an evaluation of Parental Stress by the ISP-4 self-questionnaire. 3. Implementation of the personalized support project 4. Self-assessment of parental stress using the ISP-4 self-questionnaire (child admitted to intensive care or resuscitation unit) 5. Application of the personalised support project 6. Self-assessment of parental stress using the ISP-4 self-questionnaire (child discharged from intensive care) 7. Paramedical follow-up consultation with parents (semi-directive interview, ISP-4 self-questionnaire) and assessment of the child's psychomotor development in the child's 6th month of life

06

What researchers measure

Primary outcomes

  1. Families participation evaluation

    The participation of families in the proposed accompaniment will be evaluated by the participation rate: number of parents who participated in the study until the last stage of the protocol, number of parents who dropped out of the study and reason.

    Time frame: at the last protocol visit ( visit 6 - day 180)

Secondary outcomes

  1. Parental stress Evolution

    Evolution of parental stress by the ISP-4 self-questionnaire (Parental Stress Index)

    Time frame: between visit 1 (day -28) and visit 6 (day 180)

  2. Infant development

    Evolution of the overall score of the Bayley-4 scale (Bayley Infant and Young Child Development Scales) at 6 months of life compared to a literature cohort (neonate child).

    Time frame: at the last protocol visit ( visit 6 - day 180)

  3. Evaluation of the healthcare team adherence

    Evaluation of the adherence of the healthcare team to this new model via a Likert scale administered at the discharge of the child, and an analysis of the large items found on the accompanying sheets

    Time frame: at visit 5 ( day 60 )

  4. Evaluation of the healthcare team adherence

    Evaluation of the adherence of the healthcare team to this new model via an EVA scale administered at the discharge of the child, and an analysis of the large items found on the accompanying sheets

    Time frame: at visit 5 ( day 60 )

  5. Personal Support Project Evaluation

    Evaluation of the Personal Support Project by families using an Visual Analogue Scale.

    Time frame: at the last protocol visit ( visit 6 - day 180)

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06884046
Lead sponsor
University Hospital, Bordeaux
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Feb 6, 2025
Primary completion
Feb 6, 2027 (estimated)
Completion
Feb 6, 2027 (estimated)
Last update
Mar 19, 2025

Study contacts

Laurie PONTEINS
Contact
laurie.ponteins@chu-bordeaux.fr
+33 05 57 65 67 93 ext. +33
Amandine RUISSEL
Contact
recherche.cardioped@chu-bordeaux.fr
+33 05 57 62 32 29 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion